| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes, Gestational | 48 | 2025 | 346 | 9.080 |
Why?
|
| Pregnancy | 84 | 2025 | 1524 | 4.660 |
Why?
|
| Weight Gain | 16 | 2023 | 173 | 4.280 |
Why?
|
| Body Mass Index | 24 | 2025 | 964 | 3.360 |
Why?
|
| Overweight | 11 | 2025 | 269 | 3.320 |
Why?
|
| Pregnancy Complications | 13 | 2024 | 199 | 3.060 |
Why?
|
| Female | 109 | 2025 | 12740 | 2.930 |
Why?
|
| Obesity | 16 | 2025 | 842 | 2.690 |
Why?
|
| Exercise | 13 | 2025 | 492 | 2.620 |
Why?
|
| Humans | 115 | 2025 | 17762 | 2.620 |
Why?
|
| Adult | 76 | 2025 | 7678 | 2.410 |
Why?
|
| Premature Birth | 5 | 2023 | 137 | 2.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 19 | 2022 | 755 | 2.020 |
Why?
|
| Leiomyoma | 3 | 2025 | 13 | 1.950 |
Why?
|
| Cohort Studies | 30 | 2025 | 2586 | 1.830 |
Why?
|
| Pediatric Obesity | 7 | 2024 | 84 | 1.830 |
Why?
|
| Ethnic Groups | 10 | 2021 | 485 | 1.720 |
Why?
|
| Prenatal Care | 11 | 2024 | 129 | 1.720 |
Why?
|
| Dermatitis, Atopic | 2 | 2023 | 13 | 1.670 |
Why?
|
| Hypertension, Pregnancy-Induced | 4 | 2025 | 46 | 1.580 |
Why?
|
| Infant, Newborn | 22 | 2024 | 855 | 1.480 |
Why?
|
| Delivery of Health Care, Integrated | 5 | 2025 | 535 | 1.450 |
Why?
|
| Cesarean Section | 3 | 2021 | 30 | 1.440 |
Why?
|
| Bariatric Surgery | 2 | 2023 | 128 | 1.440 |
Why?
|
| Risk Factors | 29 | 2025 | 3356 | 1.400 |
Why?
|
| Taxes | 3 | 2025 | 24 | 1.390 |
Why?
|
| California | 32 | 2025 | 2326 | 1.360 |
Why?
|
| Depression | 7 | 2023 | 505 | 1.350 |
Why?
|
| Hypertension | 4 | 2025 | 504 | 1.320 |
Why?
|
| Prenatal Exposure Delayed Effects | 7 | 2025 | 167 | 1.310 |
Why?
|
| Pregnancy Outcome | 9 | 2023 | 156 | 1.300 |
Why?
|
| Young Adult | 28 | 2025 | 2461 | 1.220 |
Why?
|
| Life Style | 12 | 2025 | 333 | 1.190 |
Why?
|
| Telemedicine | 4 | 2024 | 186 | 1.120 |
Why?
|
| Blood Glucose | 16 | 2019 | 343 | 1.080 |
Why?
|
| Pregnancy Trimesters | 2 | 2016 | 30 | 1.070 |
Why?
|
| Child Development | 3 | 2024 | 54 | 1.050 |
Why?
|
| Postpartum Period | 8 | 2025 | 96 | 1.040 |
Why?
|
| Insulin Resistance | 4 | 2014 | 134 | 1.040 |
Why?
|
| Cardiovascular Diseases | 2 | 2024 | 599 | 1.030 |
Why?
|
| Pre-Eclampsia | 2 | 2023 | 44 | 1.010 |
Why?
|
| Maternal Exposure | 3 | 2025 | 62 | 0.980 |
Why?
|
| Adolescent | 25 | 2025 | 3685 | 0.970 |
Why?
|
| Mothers | 4 | 2021 | 105 | 0.940 |
Why?
|
| Mobile Applications | 1 | 2024 | 19 | 0.940 |
Why?
|
| Sex Hormone-Binding Globulin | 2 | 2014 | 22 | 0.920 |
Why?
|
| Middle Aged | 34 | 2025 | 7988 | 0.860 |
Why?
|
| Diet | 4 | 2024 | 365 | 0.850 |
Why?
|
| Venous Thrombosis | 1 | 2022 | 21 | 0.820 |
Why?
|
| Hypoglycemic Agents | 9 | 2022 | 271 | 0.810 |
Why?
|
| Gestational Age | 5 | 2023 | 111 | 0.810 |
Why?
|
| Triglycerides | 2 | 2021 | 88 | 0.810 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2023 | 55 | 0.810 |
Why?
|
| Pulmonary Embolism | 1 | 2022 | 44 | 0.810 |
Why?
|
| Skin Neoplasms | 1 | 2023 | 57 | 0.790 |
Why?
|
| Glyburide | 1 | 2022 | 7 | 0.790 |
Why?
|
| Vitamin D | 1 | 2022 | 76 | 0.780 |
Why?
|
| Longitudinal Studies | 13 | 2025 | 719 | 0.740 |
Why?
|
| Weight Reduction Programs | 2 | 2019 | 52 | 0.720 |
Why?
|
| Child, Preschool | 12 | 2025 | 1419 | 0.710 |
Why?
|
| Cholesterol, HDL | 1 | 2021 | 81 | 0.710 |
Why?
|
| Case-Control Studies | 11 | 2025 | 1120 | 0.710 |
Why?
|
| Odds Ratio | 12 | 2016 | 671 | 0.710 |
Why?
|
| Child | 17 | 2025 | 2491 | 0.670 |
Why?
|
| Breast Neoplasms | 4 | 2023 | 954 | 0.670 |
Why?
|
| Male | 27 | 2025 | 10106 | 0.670 |
Why?
|
| Weight Loss | 7 | 2025 | 305 | 0.660 |
Why?
|
| Metformin | 5 | 2018 | 57 | 0.650 |
Why?
|
| Retrospective Studies | 9 | 2025 | 2461 | 0.650 |
Why?
|
| Pain Management | 1 | 2019 | 58 | 0.650 |
Why?
|
| Prospective Studies | 14 | 2025 | 1279 | 0.630 |
Why?
|
| Infant | 11 | 2024 | 1192 | 0.610 |
Why?
|
| Stress, Psychological | 3 | 2022 | 141 | 0.590 |
Why?
|
| Precision Medicine | 1 | 2018 | 28 | 0.590 |
Why?
|
| Analgesics, Opioid | 2 | 2023 | 246 | 0.580 |
Why?
|
| Quality Improvement | 1 | 2019 | 194 | 0.580 |
Why?
|
| Hispanic Americans | 7 | 2021 | 404 | 0.570 |
Why?
|
| Fetal Macrosomia | 5 | 2017 | 26 | 0.540 |
Why?
|
| Residence Characteristics | 4 | 2025 | 250 | 0.510 |
Why?
|
| Lipids | 1 | 2016 | 78 | 0.510 |
Why?
|
| Continental Population Groups | 4 | 2016 | 302 | 0.510 |
Why?
|
| Dyslipidemias | 1 | 2016 | 62 | 0.500 |
Why?
|
| Glucose Tolerance Test | 9 | 2022 | 108 | 0.480 |
Why?
|
| Pandemics | 5 | 2023 | 287 | 0.480 |
Why?
|
| Logistic Models | 10 | 2016 | 927 | 0.470 |
Why?
|
| Liver | 1 | 2014 | 32 | 0.460 |
Why?
|
| Self Report | 1 | 2016 | 253 | 0.460 |
Why?
|
| Adiponectin | 1 | 2013 | 21 | 0.430 |
Why?
|
| Electronic Health Records | 2 | 2018 | 697 | 0.430 |
Why?
|
| Cross-Sectional Studies | 9 | 2022 | 1330 | 0.430 |
Why?
|
| Pharmacogenomic Variants | 3 | 2018 | 7 | 0.430 |
Why?
|
| Biomarkers | 6 | 2024 | 303 | 0.420 |
Why?
|
| Motivational Interviewing | 2 | 2024 | 33 | 0.420 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2018 | 379 | 0.410 |
Why?
|
| Vitamins | 2 | 2022 | 64 | 0.400 |
Why?
|
| Prehypertension | 1 | 2012 | 22 | 0.400 |
Why?
|
| Inflammation | 1 | 2012 | 63 | 0.390 |
Why?
|
| Neonatal Abstinence Syndrome | 2 | 2023 | 5 | 0.380 |
Why?
|
| Autism Spectrum Disorder | 2 | 2024 | 164 | 0.370 |
Why?
|
| Risk Reduction Behavior | 4 | 2020 | 108 | 0.370 |
Why?
|
| Women's Health | 2 | 2023 | 201 | 0.370 |
Why?
|
| Blood Pressure | 3 | 2025 | 302 | 0.350 |
Why?
|
| Risk | 4 | 2014 | 517 | 0.350 |
Why?
|
| United States | 11 | 2025 | 4003 | 0.350 |
Why?
|
| Prenatal Diagnosis | 1 | 2010 | 17 | 0.340 |
Why?
|
| Glucose Intolerance | 4 | 2015 | 45 | 0.330 |
Why?
|
| Hypoglycemia | 2 | 2006 | 49 | 0.330 |
Why?
|
| Complementary Therapies | 3 | 2004 | 46 | 0.330 |
Why?
|
| Thiazolidinediones | 3 | 2015 | 52 | 0.320 |
Why?
|
| Lactation | 2 | 2024 | 52 | 0.310 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2015 | 56 | 0.310 |
Why?
|
| Poverty | 3 | 2025 | 167 | 0.300 |
Why?
|
| Insulin | 3 | 2022 | 206 | 0.300 |
Why?
|
| Pregnancy Trimester, First | 3 | 2020 | 40 | 0.300 |
Why?
|
| Surveys and Questionnaires | 6 | 2017 | 1321 | 0.300 |
Why?
|
| Preconception Care | 2 | 2021 | 44 | 0.290 |
Why?
|
| Health Behavior | 5 | 2025 | 360 | 0.290 |
Why?
|
| Breast Feeding | 4 | 2014 | 137 | 0.290 |
Why?
|
| Dietary Supplements | 3 | 2004 | 87 | 0.290 |
Why?
|
| Environmental Pollutants | 2 | 2025 | 48 | 0.290 |
Why?
|
| Treatment Outcome | 6 | 2023 | 1260 | 0.280 |
Why?
|
| Prevalence | 7 | 2019 | 886 | 0.280 |
Why?
|
| Social Class | 3 | 2025 | 121 | 0.280 |
Why?
|
| Androgens | 1 | 2007 | 12 | 0.280 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2007 | 12 | 0.280 |
Why?
|
| European Continental Ancestry Group | 6 | 2016 | 529 | 0.280 |
Why?
|
| Patient Education as Topic | 4 | 2024 | 212 | 0.280 |
Why?
|
| Infant, Small for Gestational Age | 2 | 2024 | 57 | 0.270 |
Why?
|
| Hyperbilirubinemia, Neonatal | 1 | 2006 | 16 | 0.270 |
Why?
|
| Aged | 10 | 2025 | 6150 | 0.250 |
Why?
|
| Memory, Episodic | 1 | 2025 | 5 | 0.250 |
Why?
|
| Parabens | 1 | 2025 | 4 | 0.250 |
Why?
|
| Memory Disorders | 1 | 2025 | 8 | 0.250 |
Why?
|
| Uterine Neoplasms | 1 | 2025 | 13 | 0.250 |
Why?
|
| Healthy Lifestyle | 1 | 2025 | 16 | 0.240 |
Why?
|
| Organophosphates | 1 | 2024 | 9 | 0.240 |
Why?
|
| Flame Retardants | 1 | 2024 | 11 | 0.240 |
Why?
|
| Databases, Factual | 3 | 2019 | 315 | 0.240 |
Why?
|
| Internal-External Control | 1 | 2004 | 12 | 0.240 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 568 | 0.230 |
Why?
|
| Food Supply | 1 | 2024 | 36 | 0.230 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 2 | 2024 | 11 | 0.230 |
Why?
|
| Cognitive Dysfunction | 1 | 2025 | 50 | 0.230 |
Why?
|
| Neoplasms | 4 | 2015 | 444 | 0.230 |
Why?
|
| Motivation | 1 | 2025 | 131 | 0.230 |
Why?
|
| Social Segregation | 1 | 2023 | 2 | 0.230 |
Why?
|
| Obstetric Labor, Premature | 1 | 2003 | 9 | 0.220 |
Why?
|
| Menopause | 2 | 2021 | 68 | 0.220 |
Why?
|
| Child Health | 2 | 2024 | 35 | 0.220 |
Why?
|
| Hypersensitivity | 1 | 2003 | 18 | 0.220 |
Why?
|
| Eclampsia | 1 | 2023 | 12 | 0.220 |
Why?
|
| Prediabetic State | 1 | 2024 | 56 | 0.220 |
Why?
|
| Fruit | 2 | 2020 | 79 | 0.220 |
Why?
|
| Ideal Body Weight | 2 | 2020 | 10 | 0.220 |
Why?
|
| Vegetables | 2 | 2020 | 87 | 0.220 |
Why?
|
| Control Groups | 1 | 2023 | 2 | 0.210 |
Why?
|
| Glycated Hemoglobin A | 4 | 2017 | 216 | 0.210 |
Why?
|
| Fetal Growth Retardation | 1 | 2023 | 11 | 0.210 |
Why?
|
| Health Status | 2 | 2004 | 298 | 0.210 |
Why?
|
| Glucose | 1 | 2023 | 30 | 0.210 |
Why?
|
| Communicable Disease Control | 1 | 2023 | 18 | 0.210 |
Why?
|
| Triclosan | 1 | 2022 | 4 | 0.210 |
Why?
|
| Diabetes Mellitus | 3 | 2024 | 487 | 0.210 |
Why?
|
| Folic Acid | 1 | 2022 | 32 | 0.210 |
Why?
|
| Attitude to Health | 4 | 2017 | 164 | 0.210 |
Why?
|
| Antihypertensive Agents | 1 | 2024 | 161 | 0.200 |
Why?
|
| Depression, Postpartum | 1 | 2022 | 18 | 0.200 |
Why?
|
| Accelerometry | 1 | 2022 | 39 | 0.200 |
Why?
|
| Sleep | 1 | 2022 | 58 | 0.200 |
Why?
|
| Cholesterol | 2 | 2012 | 106 | 0.200 |
Why?
|
| Autistic Disorder | 1 | 2023 | 100 | 0.200 |
Why?
|
| Alcohol Drinking | 2 | 2020 | 373 | 0.200 |
Why?
|
| Prostatic Neoplasms | 3 | 2015 | 262 | 0.190 |
Why?
|
| Cannabis | 1 | 2023 | 82 | 0.190 |
Why?
|
| Confidence Intervals | 2 | 2016 | 237 | 0.190 |
Why?
|
| Severity of Illness Index | 1 | 2023 | 455 | 0.180 |
Why?
|
| Maternal Age | 1 | 2021 | 77 | 0.180 |
Why?
|
| Cluster Analysis | 2 | 2018 | 90 | 0.180 |
Why?
|
| Referral and Consultation | 2 | 2012 | 169 | 0.180 |
Why?
|
| Cholesterol, LDL | 1 | 2021 | 119 | 0.170 |
Why?
|
| Research Design | 3 | 2019 | 376 | 0.170 |
Why?
|
| Organic Cation Transport Proteins | 2 | 2017 | 3 | 0.170 |
Why?
|
| Energy Intake | 1 | 2020 | 101 | 0.170 |
Why?
|
| Incidence | 3 | 2013 | 1266 | 0.170 |
Why?
|
| Pain, Postoperative | 1 | 2019 | 17 | 0.170 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 36 | 0.160 |
Why?
|
| Developmental Disabilities | 1 | 2019 | 52 | 0.160 |
Why?
|
| Socioeconomic Factors | 3 | 2019 | 630 | 0.160 |
Why?
|
| Program Evaluation | 1 | 2019 | 223 | 0.150 |
Why?
|
| Carboxypeptidases A | 1 | 2018 | 1 | 0.150 |
Why?
|
| Eye Proteins | 1 | 2018 | 14 | 0.150 |
Why?
|
| Asian Americans | 3 | 2016 | 176 | 0.150 |
Why?
|
| Health Status Disparities | 2 | 2016 | 146 | 0.150 |
Why?
|
| Fasting | 2 | 2014 | 48 | 0.140 |
Why?
|
| Pregnancy Trimester, Second | 2 | 2010 | 25 | 0.140 |
Why?
|
| Membrane Transport Proteins | 1 | 2017 | 4 | 0.140 |
Why?
|
| Washington | 5 | 2004 | 382 | 0.140 |
Why?
|
| Glucose Transporter Type 2 | 1 | 2016 | 1 | 0.140 |
Why?
|
| Environment | 1 | 2016 | 51 | 0.140 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2016 | 8 | 0.140 |
Why?
|
| Behavior Therapy | 2 | 2015 | 146 | 0.140 |
Why?
|
| Pregnancy in Diabetics | 1 | 2016 | 21 | 0.130 |
Why?
|
| Delivery, Obstetric | 1 | 2016 | 16 | 0.130 |
Why?
|
| Membrane Proteins | 1 | 2016 | 39 | 0.130 |
Why?
|
| Lipoproteins, HDL | 1 | 2016 | 7 | 0.130 |
Why?
|
| Lipoproteins, LDL | 1 | 2016 | 15 | 0.130 |
Why?
|
| African Americans | 3 | 2016 | 472 | 0.130 |
Why?
|
| Mexican Americans | 2 | 2013 | 45 | 0.130 |
Why?
|
| Postnatal Care | 2 | 2014 | 21 | 0.130 |
Why?
|
| Waist Circumference | 2 | 2013 | 39 | 0.130 |
Why?
|
| Exercise Therapy | 1 | 2016 | 71 | 0.130 |
Why?
|
| Disease Progression | 1 | 2016 | 264 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2016 | 121 | 0.120 |
Why?
|
| Managed Care Programs | 1 | 2016 | 325 | 0.120 |
Why?
|
| Language | 1 | 2015 | 53 | 0.120 |
Why?
|
| Pharmacogenetics | 1 | 2014 | 15 | 0.120 |
Why?
|
| Transcription Factors | 1 | 2014 | 19 | 0.120 |
Why?
|
| Proteinuria | 1 | 2014 | 26 | 0.110 |
Why?
|
| Early Diagnosis | 1 | 2014 | 38 | 0.110 |
Why?
|
| Social Identification | 1 | 2013 | 7 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 1 | 2015 | 67 | 0.110 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 415 | 0.110 |
Why?
|
| Patient Selection | 1 | 2015 | 190 | 0.110 |
Why?
|
| Aged, 80 and over | 5 | 2017 | 1923 | 0.110 |
Why?
|
| Time Factors | 2 | 2008 | 1093 | 0.100 |
Why?
|
| Educational Status | 4 | 2023 | 200 | 0.100 |
Why?
|
| Sex Ratio | 1 | 2012 | 2 | 0.100 |
Why?
|
| Leukocyte Count | 1 | 2012 | 21 | 0.100 |
Why?
|
| Blood Pressure Determination | 1 | 2012 | 57 | 0.100 |
Why?
|
| Prognosis | 1 | 2013 | 609 | 0.100 |
Why?
|
| Body Weight | 2 | 2025 | 223 | 0.090 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2011 | 27 | 0.090 |
Why?
|
| Health Promotion | 1 | 2014 | 281 | 0.090 |
Why?
|
| Feeding Behavior | 2 | 2003 | 166 | 0.090 |
Why?
|
| Anxiety | 2 | 2022 | 151 | 0.090 |
Why?
|
| Genome-Wide Association Study | 3 | 2018 | 249 | 0.090 |
Why?
|
| Health Services | 1 | 2001 | 112 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 1213 | 0.090 |
Why?
|
| Patient Satisfaction | 3 | 2004 | 212 | 0.080 |
Why?
|
| Alcohol-Related Disorders | 1 | 2009 | 55 | 0.070 |
Why?
|
| Alcoholism | 1 | 2001 | 348 | 0.070 |
Why?
|
| Ethinyl Estradiol | 1 | 2007 | 4 | 0.070 |
Why?
|
| Organic Cation Transporter 2 | 2 | 2017 | 3 | 0.070 |
Why?
|
| Hyperbilirubinemia | 1 | 2006 | 9 | 0.070 |
Why?
|
| Parity | 2 | 2020 | 74 | 0.070 |
Why?
|
| Age Distribution | 2 | 2004 | 246 | 0.070 |
Why?
|
| Quality of Life | 3 | 2004 | 510 | 0.070 |
Why?
|
| Phenotype | 2 | 2017 | 151 | 0.060 |
Why?
|
| Neuropsychological Tests | 1 | 2025 | 41 | 0.060 |
Why?
|
| Prenatal Nutritional Physiological Phenomena | 1 | 2024 | 5 | 0.060 |
Why?
|
| Esters | 1 | 2024 | 5 | 0.060 |
Why?
|
| Cities | 1 | 2024 | 29 | 0.060 |
Why?
|
| Linear Models | 2 | 2016 | 231 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2004 | 382 | 0.060 |
Why?
|
| Sex Distribution | 1 | 2004 | 190 | 0.060 |
Why?
|
| Censuses | 1 | 2023 | 31 | 0.060 |
Why?
|
| Tobacco | 1 | 2023 | 14 | 0.050 |
Why?
|
| Stillbirth | 1 | 2023 | 29 | 0.050 |
Why?
|
| Ethanol | 1 | 2023 | 22 | 0.050 |
Why?
|
| Directive Counseling | 2 | 2014 | 25 | 0.050 |
Why?
|
| Phenol | 1 | 2022 | 4 | 0.050 |
Why?
|
| Benzhydryl Compounds | 1 | 2022 | 23 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2022 | 72 | 0.050 |
Why?
|
| Phenols | 1 | 2022 | 34 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2014 | 218 | 0.050 |
Why?
|
| Adaptation, Psychological | 1 | 2022 | 77 | 0.050 |
Why?
|
| Minority Groups | 1 | 2022 | 101 | 0.050 |
Why?
|
| Anxiety Disorders | 1 | 2022 | 91 | 0.050 |
Why?
|
| Colonic Neoplasms | 1 | 2002 | 156 | 0.050 |
Why?
|
| Dietary Fats | 1 | 2001 | 91 | 0.050 |
Why?
|
| Vasomotor System | 1 | 2020 | 5 | 0.050 |
Why?
|
| Sweating | 1 | 2020 | 9 | 0.050 |
Why?
|
| Motor Activity | 2 | 2014 | 212 | 0.040 |
Why?
|
| Hot Flashes | 1 | 2020 | 39 | 0.040 |
Why?
|
| Mental Health | 1 | 2022 | 166 | 0.040 |
Why?
|
| Child Health Services | 1 | 2001 | 113 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2004 | 390 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 2020 | 45 | 0.040 |
Why?
|
| Thinness | 1 | 2020 | 30 | 0.040 |
Why?
|
| Intelligence | 1 | 2019 | 9 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2018 | 3 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2018 | 155 | 0.040 |
Why?
|
| Telephone | 2 | 2014 | 161 | 0.040 |
Why?
|
| Hospitalization | 1 | 2023 | 808 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 328 | 0.040 |
Why?
|
| Counseling | 1 | 2019 | 189 | 0.040 |
Why?
|
| Maternal Behavior | 1 | 2017 | 13 | 0.040 |
Why?
|
| Octamer Transcription Factor-1 | 1 | 2017 | 1 | 0.040 |
Why?
|
| Sports | 1 | 2017 | 21 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2016 | 7 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2003 | 615 | 0.030 |
Why?
|
| Social Environment | 1 | 2017 | 88 | 0.030 |
Why?
|
| Genotype | 1 | 2017 | 227 | 0.030 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2016 | 90 | 0.030 |
Why?
|
| African Continental Ancestry Group | 1 | 2016 | 162 | 0.030 |
Why?
|
| Sp1 Transcription Factor | 1 | 2014 | 1 | 0.030 |
Why?
|
| PPAR alpha | 1 | 2014 | 1 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2014 | 4 | 0.030 |
Why?
|
| Homozygote | 1 | 2014 | 13 | 0.030 |
Why?
|
| Models, Biological | 1 | 2014 | 30 | 0.030 |
Why?
|
| Homeostasis | 1 | 2014 | 11 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2014 | 46 | 0.030 |
Why?
|
| Confounding Factors (Epidemiology) | 1 | 2014 | 86 | 0.030 |
Why?
|
| Psychometrics | 1 | 2013 | 121 | 0.030 |
Why?
|
| Body Composition | 1 | 2013 | 83 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 381 | 0.030 |
Why?
|
| Infant, Low Birth Weight | 1 | 2012 | 35 | 0.020 |
Why?
|
| Bottle Feeding | 1 | 2011 | 8 | 0.020 |
Why?
|
| Utilization Review | 1 | 2001 | 53 | 0.020 |
Why?
|
| Patient Admission | 1 | 2001 | 72 | 0.020 |
Why?
|
| Algorithms | 1 | 2013 | 239 | 0.020 |
Why?
|
| Length of Stay | 1 | 2001 | 181 | 0.020 |
Why?
|
| Recurrence | 1 | 2011 | 188 | 0.020 |
Why?
|
| Mass Screening | 2 | 2009 | 677 | 0.020 |
Why?
|
| Sex Factors | 2 | 2003 | 644 | 0.020 |
Why?
|
| Registries | 1 | 2012 | 472 | 0.020 |
Why?
|
| Fetal Diseases | 1 | 2006 | 8 | 0.020 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2006 | 34 | 0.020 |
Why?
|
| Personal Autonomy | 1 | 2003 | 4 | 0.010 |
Why?
|
| Income | 1 | 2002 | 90 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2003 | 305 | 0.010 |
Why?
|
| Food Labeling | 1 | 2001 | 3 | 0.010 |
Why?
|
| SEER Program | 1 | 2001 | 91 | 0.010 |
Why?
|
| Diet Surveys | 1 | 2001 | 57 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2001 | 300 | 0.010 |
Why?
|
| Age Factors | 1 | 2003 | 918 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2001 | 264 | 0.010 |
Why?
|